摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2-Furylmethyl)-1,3-diazinane-2,4,6-trione | 361992-29-2

中文名称
——
中文别名
——
英文名称
1-(2-Furylmethyl)-1,3-diazinane-2,4,6-trione
英文别名
1-(Furan-2-ylmethyl)-1,3-diazinane-2,4,6-trione
1-(2-Furylmethyl)-1,3-diazinane-2,4,6-trione化学式
CAS
361992-29-2
化学式
C9H8N2O4
mdl
MFCD00104257
分子量
208.174
InChiKey
WNSAVOLNDMMVNP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.222
  • 拓扑面积:
    79.6
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
    申请人:Mustelin Tomas
    公开号:US20090105240A1
    公开(公告)日:2009-04-23
    The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.
    本公开涉及治疗白血病、白血病前期病症、以及骨髓增生异常综合征和急性髓系白血病的方法。本公开还涉及可用于治疗白血病、白血病前期病症、以及骨髓增生异常综合征和急性髓系白血病的化合物。本公开还涉及用于识别可用于治疗白血病、白血病前期病症、以及骨髓增生异常综合征的化合物的方法。
  • METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME
    申请人:Mustelin Tomas
    公开号:US20120095032A1
    公开(公告)日:2012-04-19
    The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.
查看更多